Clinical Trials Browser

Phase 1/2 × INDUSTRY × AZD3759 × Clear all

NCT03360929 2022-11-25

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms